表紙
市場調查報告書

血友病的全球市場分析:各類型(A型血友病,B型血友病,C型血友病),治療(隨選補充療法,定期的補充療法),各治療法(補充療法,基因治療) 2019年∼2026年

Hemophilia Market Size, Share & Trends Analysis Report By Type (Type A, Type B, Type C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Gene Therapy), By Region, And Segment Forecasts, 2020 - 2027

出版商 Grand View Research, Inc. 商品編碼 368045
出版日期 內容資訊 英文 90 Pages
商品交期: 2-3個工作天內
價格
血友病的全球市場分析:各類型(A型血友病,B型血友病,C型血友病),治療(隨選補充療法,定期的補充療法),各治療法(補充療法,基因治療) 2019年∼2026年 Hemophilia Market Size, Share & Trends Analysis Report By Type (Type A, Type B, Type C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Gene Therapy), By Region, And Segment Forecasts, 2020 - 2027
出版日期: 2020年03月13日內容資訊: 英文 90 Pages
簡介

全球血友病市場至2026年將成長到169億美元。為了實施預防性治療進行的對象族群的診斷的必要性高漲,及政府的血友病支援計劃等促進這個市場成長。

本報告提供全球血友病市場調查,市場概要,各類型、治療、治療方法、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場佔有率,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查方法與範圍

  • 市場區隔和範圍
  • 資訊採購
  • 資訊分析
  • 市場結構和資料的視覺化
  • 資料檢驗與公開

第2章 摘要整理

  • 市場預測
  • 市場預測:各市場區隔
  • 競爭洞察

第3章 市場變數、趨勢、範圍

  • 市場預測
  • 滲透及成長預測
  • 開發平台分析:各臨床實驗階段
  • 使用者觀點分析
  • 主要終端用戶:產品、各地區/國家
  • 法律規範
  • 市場動態
  • 市場分析工具

第4章 全球血友病市場分析:各類型

  • 定義和範圍
  • 市場佔有率分析:各類型(成果值、預測值)
  • 市場區隔儀表板
  • 全球血友病市場:各類型
  • 市場規模的變化與預測:各類型
    • 血友病 A
    • B型血友病
    • 血友病 C
    • 其他

第5章 全球血友病市場分析:各治療法

  • 定義和範圍
  • 市場佔有率分析:各治療法(成果值、預測值)
  • 市場區隔儀表板
  • 全球血友病市場:各治療法
  • 市場規模的變化與預測:各治療法
    • 補充療法
    • 免疫寬恕引進療法
    • 遺傳基因療法

第6章 全球血友病市場分析:各治療

  • 定義和範圍
  • 市場佔有率分析:各治療(成果值、預測值)
  • 市場區隔儀表板
  • 全球血友病市場:各治療
  • 市場規模的變化與預測:各治療
    • 隨選補充療法(出血時補充療法)
    • 定期性補充療法

第7章 全球血友病市場分析:各地區

  • 定義和範圍
  • 市場佔有率分析:各地區(成果值、預測值)
  • 市場區隔儀表板
  • 市場概述
  • 市場佔有率 & 主要企業:各地區
  • SWOT分析:各地區
  • 市場規模的變化與預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲

第8章 競爭分析

  • 主要加入企業的近幾年的趨勢與影響分析
  • 企業區分(創新者、市場領導者、新興企業)
  • 業者情勢
  • 公開公司
  • 民營企業
  • 供應商排行榜
  • 主要企業的簡介
    • Novo Nordisk
    • Biogen.
    • 中外製藥
    • Bayer Healthcare
    • Pfizer.
    • Shire Plc
    • Baxalta (Baxter Healthcare)
    • CSL Behring.
    • Octapharma

第9章 關鍵意見領袖的說明

第10章 建議

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 978-1-68038-989-0

The global hemophilia market size is expected to reach USD 18.1 billion by 2027, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 5.5% over the forecast period. Increasing awareness of early diagnosis and treatment coupled with supportive government policies is anticipated to boost market share over the forecast period.

For instance, the NHF (National Hemophilia Foundation) allows to find treatments for inheritable bleeding disorders and help prevent complications of these disorders through research, education, and advocacy. Their programs and initiatives are in association with the Centers for Disease Control and Prevention.

In addition, U.S. Hemophilia Treatment Center Network provides specialized healthcare centers and these offer care to address all psychological, educational, and physical needs of patients suffering from the disease. These centers currently provide care to more than 35,000 adults and children with the disease and other bleeding disorders.

The key market companies are projected to adopt strategic initiatives including geographic expansion and R&D especially in developing and underdeveloped regions, such as Middle Eastern and West African countries.

For instance, BioMarin is involved in developing Valoctocogene Roxaparvovec (BMN-270) for treating type A patients and is currently under clinical trials. Furthermore, in June 2017, the U.S. FDA accepted the investigational new drug application for Sanofi's BIVV001 based on its preclinical study results.

Rising incidence of the disease is estimated to propel hemophilia market growth over the forecast period. According to the data published by the NHF, around 20,000 individuals in U.S. are suffering from this disease. In addition, approximately 75% of people with hemophilia receive inadequate treatment or have less/ no access to treatment globally.

Further key findings from the report suggest:

Hemophilia A held the largest market share in 2019 due to its increasing prevalence worldwide

Type B is expected to be the fastest growing type over the forecast period, at a CAGR of 6.8%

On-demand dominated the treatment segment over the forecast period and is expected to contribute majority of the share in 2019

Prophylaxis is estimated to be the fastest growing segment over the forecast period

Replacement therapy was expected to be the largest segment in 2019

Gene therapy dominated the therapy segment over the forecast period owing to increasing involvement of companies to develop more gene therapy for its treatment

Increasing research and development and strategic collaborations are key strategies undertaken by major players in the market space.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market segmentation & scope
  • 1.2. Information procurement
    • 1.2.1. Purchased database
    • 1.2.2. GVR's internal database
    • 1.2.3. Secondary sources & third party perspectives
    • 1.2.4. Primary research
  • 1.3. Information analysis
    • 1.3.1. Data analysis models
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hemophilia Market Variables, Trends & Scope

  • 3.1. Market Lineage outlook
    • 3.1.1. Parent/ Ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Product Pipeline Analysis
  • 3.4. Regulation Framework
  • 3.5. Market Dynamics
    • 3.5.1. Market Driver Analysis
      • 3.5.1.1. Increasing population of newborns
      • 3.5.1.2. Favorable government initiative
      • 3.5.1.3. Rising R&D and new product development
      • 3.5.1.4. Rising adoption for prophylaxis treatment
    • 3.5.2. Market Restraint Analysis
      • 3.5.2.1. High cost associated to procure treatment
  • 3.6. Hemophilia: Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power: Moderate due to presence of suppliers in the market
      • 3.6.1.2. Buyer Power: Low due to high cost of the treatment
      • 3.6.1.3. Substitution Threat: High due to presence of internal substitutes
      • 3.6.1.4. Threat from new entrant: Moderate due to presence of strong global presence of existing players
      • 3.6.1.5. Competitive rivalry: High due to involvement of companies into developing novel therapies
    • 3.6.2. PESTEL Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Environmental Landscape
      • 3.6.2.3. Social Landscape
      • 3.6.2.4. Technology Landscape
      • 3.6.2.5. Legal Landscape
    • 3.6.3. Major Deals & Strategic Alliances Analysis
      • 3.6.3.1. Joint Ventures
      • 3.6.3.2. Mergers & Acquisitions
      • 3.6.3.3. Licensing & Partnership
      • 3.6.3.4. Technology Collaborations
      • 3.6.3.5. Strategic Divestments

Chapter 4. Hemophilia Market: Segment Analysis, By Type, 2016 - 2027 (USD Million)

  • 4.1. Definitions & Scope
  • 4.2. Type market share analysis, 2019 & 2027
  • 4.3. Segment Dashboard
  • 4.4. Global Hemophilia Market, By Type, 2016 to 2027
  • 4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 4.5.1. Hemophilia A
    • 4.5.2. Hemophilia B
    • 4.5.3. Hemophilia C
    • 4.5.4. Others

Chapter 5. Hemophilia market: Segment Analysis, By Treatment, 2016 - 2027 (USD Million)

  • 5.1. Definitions & Scope
  • 5.2. Treatment market share analysis, 2019 & 2027
  • 5.3. Segment Dashboard
  • 5.4. Global Hemophilia Market, By Treatment, 2016 to 2027
  • 5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 5.5.1. On- demand
    • 5.5.2. Prophylaxis

Chapter 6. Hemophilia market: Segment Analysis, By Therapy, 2016 - 2027 (USD Million)

  • 6.1. Definitions & Scope
  • 6.2. Therapy market share analysis, 2019 & 2027
  • 6.3. Segment Dashboard
  • 6.4. Global Hemophilia Market, By Therapy, 2016 to 2027
  • 6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 6.5.1. Replacement therapy
    • 6.5.2. Gene therapy
    • 6.5.3. ITI therapy

Chapter 7. Hemophilia market: Regional Market Analysis, By Region, 2016 - 2027 (USD Million)

  • 7.1. Definitions & Scope
  • 7.2. Regional market share analysis, 2019 & 2027
  • 7.3. Regional Market Dashboard
  • 7.4. Regional Market Share and Leading Players, 2019
  • 7.5. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
    • 7.5.1. North America
    • 7.5.2. Europe
    • 7.5.3. Asia Pacific
    • 7.5.4. Latin America
    • 7.5.5. Middle East & Africa
  • 7.6. Market Size, & Forecasts and Trend Analysis
  • 7.7. North America
    • 7.7.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.7.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.7.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.7.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.7.5. U.S.
      • 7.7.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.7.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.7.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.7.6. Canada
      • 7.7.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.7.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.7.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.8. Europe
    • 7.8.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.8.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.8.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.8.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.5. Germany
      • 7.8.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.6. U.K.
      • 7.8.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.7. France
      • 7.8.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.8. Italy
      • 7.8.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.9. Spain
      • 7.8.9.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.9.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.9.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.9. Asia Pacific
    • 7.9.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.9.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.9.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.9.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.5. China
      • 7.9.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.6. Japan
      • 7.9.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.7. India
      • 7.9.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.8. Australia
      • 7.9.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.9. South Korea
      • 7.9.9.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.9.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.9.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.10. Latin America
    • 7.10.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.10.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.10.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.10.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.5. Brazil
      • 7.10.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.6. Mexico
      • 7.10.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.7. Argentina
      • 7.10.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.8. Colombia
      • 7.10.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.11. Middle East and Africa
    • 7.11.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.11.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.11.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.11.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.11.5. South Africa
      • 7.11.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.11.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.11.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.11.6. Saudi Arabia
      • 7.11.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.11.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.11.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.11.7. UAE
      • 7.11.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.11.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.11.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)

Chapter 8. Hemophilia market - Competitive Analysis

  • 8.1. Recent developments & impact analysis, by key market participants
  • 8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 8.3. Public Companies
    • 8.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 8.3.2. Company Market Share/Ranking, by region
    • 8.3.3. Competitive Dashboard Analysis
  • 8.4. Private Companies
    • 8.4.1. List of key emerging companies/technology disruptors/innovators
    • 8.4.2. Regional network map
    • 8.4.3. Company market position analysis
  • 8.5. Key companies profiles
    • 8.5.1. Novo Nordisk A/S
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Shire
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Chugai Pharmaceutical Co. Ltd.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bayer AG
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. CSL Behring
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. BioMarin
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Octopharma AG
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Genzyme Corporation
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Spark Therapeutics, Inc.
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 List of Abbreviation
  • TABLE 2 North America Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 3 North America Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 4 North America Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 5 North America Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 6 U.S. Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 7 U.S. Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 8 U.S. Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 9 Canada Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 10 Canada Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 11 Canada Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 12 Europe Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 13 Europe Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 14 Europe Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 15 Europe Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 16 U.K. Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 17 U.K. Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 18 U.K. Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 19 Germany Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 20 Germany Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 21 Germany Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 22 France Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 23 France Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 24 France Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 25 Italy Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 26 Italy Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 27 Italy Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 28 Spain Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 29 Spain Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 30 Spain Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 31 Asia Pacific Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 32 Asia Pacific Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 33 Asia Pacific Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 34 Asia Pacific Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 35 Japan Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 36 Japan Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 37 Japan Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 38 China Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 39 China Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 40 China Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 41 India Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 42 India Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 43 India Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 44 South Korea Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 45 South Korea Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 46 South Korea Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 47 Australia Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 48 Australia Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 49 Australia Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 50 Latin America Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 51 Latin America Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 52 Latin America Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 53 Latin America Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 54 Mexico Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 55 Mexico Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 56 Mexico Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 57 Brazil Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 58 Brazil Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 59 Brazil Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 60 Argentina Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 61 Argentina Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 62 Argentina Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 63 Columbia Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 64 Columbia Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 65 Columbia Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 66 MEA Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 67 MEA Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 68 MEA Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 69 MEA Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 70 South Africa Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 71 South Africa Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 72 South Africa Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 73 Saudi Arabia Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 74 Saudi Arabia Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 75 Saudi Arabia Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 76 UAE Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 77 UAE Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 78 UAE Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Market summary
  • FIG. 4 Market segmentation & scope
  • FIG. 5 Market size and growth prospects
  • FIG. 6 Global hemophilia market- Key market driver analysis
  • FIG. 7 Global hemophilia market - Key market restraint analysis
  • FIG. 8 Penetration & growth prospect mapping
  • FIG. 9 Global hemophilia market - Porter's analysis
  • FIG. 10 Global hemophilia market - PESTEL analysis
  • FIG. 11 Global hemophilia market type outlook key takeaways
  • FIG. 12 Global hemophilia market: Type movement analysis
  • FIG. 13 Hemophilia A market estimates, 2016 - 2027 (USD Million)
  • FIG. 14 Hemophilia B market estimates, 2016 - 2027 (USD Million)
  • FIG. 15 Hemophilia C market estimates, 2016 - 2027 (USD Million)
  • FIG. 16 Others market estimates, 2016 - 2027 (USD Million)
  • FIG. 17 Global hemophilia market treatment outlook key takeaways
  • FIG. 18 Global hemophilia market: Treatment movement analysis
  • FIG. 19 On-demand market estimates, 2016 - 2027 (USD Million)
  • FIG. 20 Prophylaxis market estimates, 2016 - 2027 (USD Million)
  • FIG. 21 Global hemophilia market therapy outlook key takeaways
  • FIG. 22 Global hemophilia market: Therapy movement analysis
  • FIG. 23 Replacement therapy market estimates, 2016 - 2027 (USD Million)
  • FIG. 24 ITI therapy market estimates, 2016 - 2027 (USD Million)
  • FIG. 25 Gene therapy market estimates, 2016 - 2027 (USD Million)
  • FIG. 26 Regional marketplace: Key takeaways
  • FIG. 27 Global hemophilia market: Regional movement analysis
  • FIG. 28 North America hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 29 U.S. hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 30 Canada hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 31 Europe hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 32 U.K. hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 33 Germany hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 34 France hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 35 Spain hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 36 Italy hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 37 Asia Pacific hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 38 Japan hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 39 China hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 40 India hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 41 South Korea hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 42 Australia hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 43 Latin America hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 44 Brazil hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 45 Mexico hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 46 Argentina hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 47 Colombia hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 48 MEA hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 49 South Africa hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 50 Saudi Arabia hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 51 UAE market, 2016 - 2027 (USD Million)
  • FIG. 52 Strategy framework